Epidemiological and Clinical Characteristics of Multiple Sclerosis in The Population of Baku City

Authors

  • A.I. Guliyeva Azerbaijan State Advanced Training Institute for Doctors names after A.Aliyev, Department of Neurology and Clinical Neurophysiology, Baku, Azerbaijan
  • R.K. Shiraliyeva Azerbaijan State Advanced Training Institute for Doctors names after A.Aliyev, Department of Neurology and Clinical Neurophysiology, Baku, Azerbaijan
  • R.R. Aliyev Azerbaijan State Advanced Training Institute for Doctors names after A.Aliyev, Department of Neurology and Clinical Neurophysiology, Baku, Azerbaijan
  • R.L. Hasanov Azerbaijan State Advanced Training Institute for Doctors names after A.Aliyev, Department of Neurology and Clinical Neurophysiology, Baku, Azerbaijan

DOI:

https://doi.org/10.61788/njn.v2i19.03

Keywords:

multiple sclerosis, attack, clinical course, Baku

Abstract

Clinical and epidemiological studies of multiple sclerosis among Baku population were carried out in 2013-2014. In total 138 people participated in the studies. It was revealed that the majority of the patients were found more often. It was found out that most of the patients were diagnosed with the multiple sclerosis several years after the manifestation of the disease. Only 49% of the patients who had undergone corticosteroid therapy in the first year of State Programmer were treated with cytostatic drugs and medicines changing the progress of the disease.

References

Şirəliyeva R.K. Kliniki nevrologiya. Baki, 2009, 528 səh.

Хабиров Ф.А., Хайбуллин Т.И., и др. Применение церебролизина у больных рассеянным склерозом в стадии регресса обострения. Журнал неврологии и психиатрии им. С.С.Корсакова. 2016; 116(12): 48-53.

Бойко А.Н., Лащ Н.Ю., и др. Сравнительное плацебо-контролируемое клиническое исследование эффективности и безопасности препаратов глатирамера ацетата 20 мг у пациентов с ремитирующим рассеянным склерозом: результаты первого года наблюдения. Журнал неврологии и психиатрии им. С.С. Корсакова (Спецвыпуск), 2016; 116: 10(2): 61-67.

European Medicines Agency. Reflection paper on the regulatory guidance for the use ofhealth-related quality of life (HRQL) measures in the evaluation of medicinal products.http://www.ema.europa. eu/ema/ema/pages.

Dhib-Jalbut S., McFarland H.F. Treatment of multiple sclerosis with interferon beta 1b. Baillieres Clin Neurol. 1997; 6(3):467-480.

Ford C.C., Johnson K.P., Lisak R.P., Panitch H.S., Shifronis G., Wolinsky J.S. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult. Scler. 2006;12(3):309-320.

Хабиров Ф.А., Аверьянова Л.А., и др. Анализ эффективности и безопасности биоаналога интерферона бета-1а для внутримышечного введения в лечении рассеянного склероза. Современная медицина: неврология/психиатрия. 2016; 1(1):21-24.

Polman C.H., Reingold S.C., Banwell B., Clanet M., et all. Diagnostic criteria for multiple sclerosis. 2010 revisions to the McDonald criteria // Annals of neurology.2011, 69 (2) : p. 292-302.

Zahoor İ., Haq E. Multiple sclerosis in İndia: İceberg or volcano // Journal of Neuroimmunology.2017; 307: p. 27.

Vahid K.M..et all. Epidemiology of multiple sclerosis in Torbat-e Heydarich (Northeast of İran) during 1982-2016. Multiple Sclerosis and Related Desorders 24(2018) 184-189.

Карева Е., Олейникова О., Семейкин А. Иммунитет – мужской и женский. /Наука и жизнь/ m.nkj.ru.

Downloads

Published

31.12.2019

How to Cite

Guliyeva, A., Shiraliyeva, R., Aliyev, R., & Hasanov, R. (2019). Epidemiological and Clinical Characteristics of Multiple Sclerosis in The Population of Baku City. National Journal of Neurology, 24–28. https://doi.org/10.61788/njn.v2i19.03

Issue

2019: No.2 (16)

Section

Original Articles

License

Copyright (c) 2026 National Association of Neurologists

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.